Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00

Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00

H.C. Wainwright initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00

Rodman & Renshaw initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $48.00

Cantor Fitzgerald initiated coverage of Bicara Therapeutics with a rating of Overweight

Morgan Stanley initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $35.00

TD Cowen initiated coverage of Bicara Therapeutics with a rating of Buy

Stifel initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $47.00

10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

DEFA14A - Bicara Therapeutics Inc. (0002023658) (Filer)

DEF 14A - Bicara Therapeutics Inc. (0002023658) (Filer)

S-8 - Bicara Therapeutics Inc. (0002023658) (Filer)

10-K - Bicara Therapeutics Inc. (0002023658) (Filer)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

144 - Bicara Therapeutics Inc. (0002023658) (Subject)

SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types. "We are excited to present s

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets:

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET. A live webcast of the presentation will be available at Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional t

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor

BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC). The results were presented in a poster session during the 2025 ASCO Gastrointestinal (GI) Cancers Symposium on Saturday, January 25, 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal gro

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended Se

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Bicara's website at www.bicara.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Bicara Therapeutics

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)